Important aspects of cost-effectiveness analysis in febrile neutropenia.
Karthaus
M
M
Boehme
A
A
Ganser
A
A
Juergens
H
H
D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005334:Fever / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000188:drug therapy* / Q000382:microbiology; D012307:Risk Factors
D000900:Anti-Bacterial Agents